The management of residuals after completion of chemotherapy in advanced seminoma is controversial. It has been proposed that fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used as a follow-up. In this study we investigated FDG-PET as a follow-up tool in advanced seminoma patients treated previously with chemotherapy or radiotherapy. Thirty-seven patients assigned to an advanced seminoma group based on CT and/or FDG-PET/CT and then treated with chemotherapy were included in the study. All these patients underwent FDG-PET/CT examination as a part of the follow-up scheme. Patients underwent retroperitoneal lymph node dissection (RPLND), radiotherapy, or were followed clinically by CT and/or PET/CT every 6 months. In 8 cases FDG-PET was positive: 5 of them underwent RPLND and 3 radiotherapy. Two patients with negative FDG-PET but positive CT also underwent RPLND. The remaining patients with negative FDG-PET results were followed up. FDG-PET/CT was false positive in one case >3 cm and one <3 cm, in 6 cases >3 cm it was true negative. While FDG-PET can find a viable tumor, there also is an important question of false positive results. It was clinically proven that a negative FDG-PET was correlated with stable disease, but we were unable to examine specimens in these cases.

Keywords:
Fluorodeoxyglucose-positron emission tomography, Seminoma, Residual lesions
1.
Thomas GM, Rider WD, Dembo AJ, et al: Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 1982;8:165–174.
2.
Peckham MJ, Horwich A, Hendry WF: Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Brit J Cancer 1985;52:7–13.
3.
Motzer R, Bosl G, Heelan R, et al: Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5:1064–1070.
4.
Puc HS, Heelan R, Mazumdar M, et al: Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454–460.
5.
Fossa SD, Oliver RT, Stenning SP, et al: Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997;33:1380–1387.
6.
Flechon A, Bompas E, Biron P, et al: Management of postchemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975–1979.
7.
Herr HW, Sheinfeld J, Puc HS, et al: Surgery for a postchemotherapy residual mass in seminoma. J Urol 1997;157:860–862.
8.
Schultz SM, Einhorn LH, Conces DJ Jr, et al: Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989;7:1497–1503.
9.
Stephens AW, Gonin R, Hutchins GD, et al: Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637–1641.
10.
Sanchez D, Zudaire JJ, Fernandez JM, et al: 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 2002;89:912–916.
11.
Bomanji JB, Costa DC, Ell PJ: Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157–164.
12.
Cerfolio RJ, Ojha B, Mukherjee S, et al: Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938–944.
13.
Becherer A, Jaeger U, Szabo M, et al: Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 2003;47:14–21.
14.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, European Association of Urology: EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011;60:304–319.
15.
De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J: Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740–3744.
16.
Ganjoo KN, Chan RJ, Sharma M, et al: Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457–3460.
17.
Becherer A, De Santis M, Karanikas G, Szabó M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K: FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005;54:284–288.
18.
Müller-Mattheis V, Reinhardt M, Gerharz CD, Fürst G, Vosberg H, Müller-Gärtner HW, Ackermann R: Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors (in German). Urologe A 1998;37:609–620.
19.
Horwich A, Paluchowska B, Norman A, et al: Residual mass following chemotherapy of seminoma. Ann Oncol 1997;8:37–40.
20.
Friedmann EL, Garnick MB, Stomper PC, et al: Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985;3:1325–1332.
21.
Ravi R, Ong J, Oliver RT, et al: The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999;83:649–653.
22.
Fléchon A, Bompas E, Biron P, et al: Management of postchemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975–1979.
23.
Gietema JA, Willemse PH, Mulder NH, et al: Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma. Eur J Cancer 1991;27:1376–1379.
24.
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–1039.
25.
Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O, Söderström KO, Joensuu H, Salminen E: Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997;33:1234–1241.
26.
Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, Tauro A, Davis ID, Hicks RJ, Bolton DM, Scott AM: 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004;64:1202–1207.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.